Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puretech Health Plc ADR (NQ: PRTC )

23.39 +2.15 (+10.12%)
Streaming Delayed Price Updated: 3:58 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Puretech Health Plc ADR

< Previous 1 2 3 4 5 6 Next >
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
From PureTech Health plc
Via Business Wire
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
From PureTech Health plc
Via Business Wire
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech to Present at CHEST 2024 Annual Meeting
From PureTech Health
Via Business Wire
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
From PureTech Health plc
Via Business Wire
PureTech Health plc – Half-Year Report
From PureTech Health plc
Via Business Wire
PureTech Appoints Michele Holcomb, PhD, to Board of Directors
From PureTech Health plc
Via Business Wire
PureTech Health: Notice of Half-Yearly Results
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
From PureTech Health plc
Via Business Wire
PureTech Health: Completion of Tender Offer & Total Voting Rights
From PureTech Health plc
Via Business Wire
PureTech Health: Results of the Tender Offer
From PureTech Health plc
Via Business Wire
PureTech Announces Change of Board Role
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
From PureTech Health plc
Via Business Wire
PureTech Health: Results of Annual General Meeting
From PureTech Health plc
Via Business Wire
PureTech Health: Result of General Meeting
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
From PureTech Health plc
Via Business Wire
PureTech to Present at the Jefferies Global Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
From PureTech Health plc
Via Business Wire
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
From PureTech Health plc
Via Business Wire
PureTech Announces Annual Results for Year Ended December 31, 2023
From PureTech Health plc
Via Business Wire
PureTech Health: Notice of Results
From PureTech Health plc
Via Business Wire
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
From PureTech Health plc
Via Business Wire
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
From PureTech Health plc 
Via Business Wire
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
From PureTech Health plc
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.